ClinicalTrials.gg
CompletedNCT05784246SHINE-2Updated Jun 3, 2026

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

A Phase 3 interventional study of Mirikizumab IV and Mirikizumab SC in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 34 sites in 11 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
11th of 13
63 · median 172
Started
2023
with 1 other
Phase 3
7 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 11th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 9th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

Read the detailed description

Participants who complete the study will have the option to enter the long-term extension Study I6T-MC-AMAZ (AMAZ).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females weighing ≥10 kg and ≥2 and \<18 years old at the time of consent for screening.
  • Have moderate to severe UC.
  • Have failed , biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.
  • Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.

Exclusion criteria

Exclusion Criteria:

  • Have Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.
  • Have immune deficiency syndrome.
  • Previous bowel resection or intestinal surgery.
  • Evidence of toxic megacolon.
  • History or current evidence of cancer of the gastrointestinal tract.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Mirikizumab Weight-Based Group 1

    Experimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).

    Drug: Mirikizumab IV · Drug: Mirikizumab SC

  • Experimental
    Mirikizumab Weight-Based Group 2

    Experimental: Participants will receive mirikizumab weight-based dosing IV or SC.

    Drug: Mirikizumab IV · Drug: Mirikizumab SC

  • Experimental
    Mirikizumab Weight-Based Group 3

    Experimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.

    Drug: Mirikizumab IV · Drug: Mirikizumab SC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical Responders

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Percentage of Participants in MMS Clinical Remission

    Time frame: Week 12

  2. Percentage of Participants in MMS Clinical Response

    Time frame: Week 12

  3. Percentage of Participants with Endoscopic Remission

    Time frame: Week 12

  4. Percentage of Participants with Endoscopic Improvement

    Time frame: Week 12

  5. Percentage of Participants Achieving Pediatric Ulcerative Colitis Activity Index (PUCAI) Clinical Response

    Time frame: Week 12

  6. Percentage of Participants Achieving PUCAI Clinical Remission

    Time frame: Week 12

  7. Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement

    Time frame: Week 12

  8. Percentage of Participants Achieving MMS Clinical Response

    Time frame: Week 52

  9. Percentage of Participants Achieving MMS Clinical Remission

    Time frame: Week 52

  10. Percentage of Participants Achieving PUCAI Clinical Response

    Time frame: Week 52

  11. Percentage of Participants Achieving PUCAI Clinical Remission

    Time frame: Week 52

  12. Percentage of Participants Achieving Endoscopic Remission

    Time frame: Week 52

  13. Percentage of Participants Achieving Endoscopic Improvement

    Time frame: Week 52

  14. Percentage of Participants Achieving MMS Clinical Remission without Surgery at Week 52 among Clinical Responders at Week 12 and without the Use of Corticosteroids

    Time frame: Baseline to Week 52

  15. Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement

    Time frame: Week 52

  16. Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab

    PK: AUC of Mirikizumab

    Time frame: Baseline to Week 52

  17. PK: Cmax of Mirikizumab

    Time frame: Baseline to Week 52

07

Study locations

34 sites
  • University of California, San Francisco
    San Francisco, California 94158, United States
  • Children's Center for Digestive Health Care, LLC
    Atlanta, Georgia 30342, United States
  • Riley Childrens Hospital
    Indianapolis, Indiana 46202, United States
  • Washington University
    St Louis, Missouri 63110-1010, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • UZA
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • The Hospital for Sick Children
    Toronto, M5G 0A4, Canada
  • Hôpital Necker - Enfants Malades
    Paris, 75015, France
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55131, Germany
  • LMU-Campus Innenstadt
    München, 80337, Germany
  • Helios Klinikum Wuppertal
    Wuppertal, 42283, Germany
  • Shaare Zedek
    Jerusalem, 9103102, Israel
  • Hadassah University Hospital, Ein Kerem
    Jerusalem, 911200, Israel
  • Schneider Children's Medical Center
    Petah Tikva, 4920235, Israel
  • King Fahad Medical City
    Rishon LeZiyyon, 70300, Israel
  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
    Florence, 50139, Italy
  • Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza
    Roma, 00161, Italy
  • Juntendo University Hospital
    Bunkyō City, 113-8431, Japan
  • Institute of Science Tokyo Hospital
    Bunkyō City, 113-8519, Japan
  • Kokikai Tsujinaka Hospital Kashiwanoha
    Kashiwa-shi, 277-0871, Japan
  • Saga University Hospital
    Saga, 849-8501, Japan
  • National Center for Child Health and Development
    Setagaya-ku, 157-8535, Japan
  • Yokohama City University Medical Center, Center of IBD
    Yokohama, 232-0024, Japan
  • Gabinet Lekarski Bartosz Korczowski
    Rzeszów, 35-302, Poland
  • Twoja Przychodnia-Szczecińskie Centrum Medyczne
    Szczecin, 71-434, Poland
  • Medical Network Spółka z o. o., WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, 04-501, Poland
  • Instytut 'Pomnik - Centrum Zdrowia Dziecka
    Warsaw, 04-730, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Kyungpook National University Chilgok Hospital
    Daegu, 41404, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Sheffield Children's Hospital
    Sheffield, S102TH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2026, 29 months.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 29 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Nov 22, 2023
Primary completionActual
May 1, 2026
CompletionActual
May 1, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05784246
Responsible party
Sponsor
First posted
Mar 24, 2023
Start date
Nov 22, 2023
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Jun 3, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion